NASDAQ · ICLR

Icon PLC

$165.76 -$4.56 (-2.68%) 1D After hours

Key Metrics

$12.79B
Market cap
71.07×
P/E · TTM
$8.28B
Revenue · TTM
$179.94M
Net income
EPS · TTM $2.22
Dividend yield
Free cash flow $758.89M
Beta · 1Y 1.47
EBITDA · TTM $774.39M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Feb 13
    The stock moved +16.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 13
  • Feb 12
    From its Jan 29 high, the share price fell 57%.

    Peak close $185.89 on Jan 29; trough close $80.08 on Feb 12. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -57%
  • Feb 12
    The stock moved -39.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 12

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$12.79B
Enterprise value$14.89B
Shares outstanding77.1M
52-wk range$66.57 – $203.91
Avg volume · 20D795.4K
Net cash −$2.10B
Book value / share$114.93
ExchangeNASDAQ
About Icon PLC
IPO dateMay 15, 1998
Employees40100

Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E71.07
P/S1.54
P/FCF16.85
EV/EBITDA19.23
EV/Sales1.80
Graham №$75.83

Profitability

Gross
Operating 4.8%
Net 2.2%
FCF 9.2%
ROE / ROIC 1.9% · —

Financial Health

Current ratio1.14
Quick ratio
Debt / equity0.31
Debt / EBITDA 3.70
Net cash −$2.10B
Working capital$437.80M

Cash Flow · TTM

Operating CF $934.97M
Capex −$176.08M
Free cash flow $758.89M
Buybacks $500.00M
Dividends paid
Shareholder yield 3.9%

Piotroski F-Score

5 / 9
Middling fundamentals · 5 of 9 signals passing

Altman Z-Score

1.9
Grey zone (1.81–2.99) · monitor

Graham Number vs Price

$75.83 vs $165.76
Trades 2.2× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings